In certain embodiments, any controlled-release otic formulation described herein increases the exposure time of an active agent and decreases the C max in otic fluids (e.g., endolymph and/or perilymph) by about 40%, about 30%, about 20%, or about 10%, compared to a formulation that is not a controlled-release otic formulation
Un essai de plus grande envergure, men sur 125 patients diabtiques de type 2 supplments 500 mg par jour pendant six mois, a confirm cette bonne tolrance
Our study showed that liraglutide effectively prevented IR in PA-exposed L6 myotubes by activating autophagy via SESN2
Its status as a once-weekly injectable makes it a powerful option for many, now more accessible through insurance coverage that recognizes obesity as a treatable condition
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Birben E., Sahiner U.M., Sackesen C., Erzurum S., Kalayci O